Tuijin Jishu/Journal of Propulsion Technology
ISSN: 1001-4055
Vol. 44 No. 6 (2023)

Building AI-driven Models for Personalized Cancer Prediction

[1]Dr.B.Leelavathi, [2]Mrs.V.Leelavathy, [3]Mrs. S. Ananthi
[1]Associate professor,
Dr.NGP College of Arts and Science.
[2]Assistant Professor,
PPG CAS
[3]Assistant Professor, PPG CAS

Abstract

Artificial Intelligence (AI) has significantly shaped the landscape of cancer prediction across various domains. This in-depth analysis explores the diverse applications of AI in oncology, covering comparative assessments of machine learning algorithms, the significance of deep learning in early cancer detection, and the integration of multi-omics data, ethical considerations, real-time risk assessment, transfer learning, explainable AI, and challenges in clinical implementation.The exploration begins with a comparative evaluation of machine learning algorithms, focusing on their precision, interpretability, and computational efficiency in predicting cancer risks or outcomes. The study then delves into deep learning models, specifically examining Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs), and their effectiveness in early cancer detection using medical imaging and patient records over time.The incorporation of multi-omics data through AI techniques underscores its crucial role in precise cancer prediction, prognosis, and advancements in personalized medicine, leveraging genomics, transcriptomics, proteomics, and epigenomics data. Ethical considerations surrounding AI in cancer prediction, including patient privacy, fairness, interpretability, and autonomy, highlight the importance of transparent and ethically sound AI applications in healthcare.Additionally, the review explores real-time risk assessment and transfer learning, emphasizing their adaptability to dynamic patient data and optimization of models with limited datasets. The significance of explainable AI methodologies in enhancing clinical acceptance is also discussed, emphasizing their crucial role in creating transparent predictive models.Furthermore, the overview addresses challenges and opportunities in deploying AI in clinical settings, recognizing obstacles in data integration, interpretability, and ethical compliance. It highlights AI's potential to revolutionize cancer care through longitudinal studies for prognostic predictions. This comprehensive overview underscores AI's substantial impact on cancer prediction, identifying opportunities, challenges, and ethical considerations, and emphasizes the responsible integration of AI into oncology research and clinical practice.

Keywords: Artificial intelligence, cancer prediction, Convolutional Neural Networks

Introduction

In recent times, the intersection of artificial intelligence (AI) and oncology has triggered a transformative shift in the dynamics of cancer prediction, diagnosis, and treatment. The application of AI algorithms, particularly in predictive analytics, has led to ground-breaking advancements in healthcare, particularly within cancer prognosis and risk assessment. As the demand for increasingly accurate, personalized, and timely predictions grows, AI-driven methodologies have become indispensable tools for harnessing complex datasets to predict cancer risks, outcomes, and progression.

This emerging field of AI in cancer prediction takes a holistic approach, covering various aspects such as the comparative analysis of machine learning algorithms, the integration of multi-omics data, the implementation of explainable AI, real-time risk assessment, and longitudinal studies for prognostic predictions. Each facet of AI application in cancer prediction presents distinct opportunities and challenges, underscoring the need for thorough research and critical evaluation.

The comparative analysis of machine learning algorithms yields valuable insights into the most effective predictive models for different cancer types, aiding in the selection of optimal algorithms based on dataset characteristics and clinical relevance. The integration of multi-omics data not only provides a comprehensive understanding of cancer biology but also facilitates the development of precise predictive models tailored to individual molecular profiles. Additionally, ethical considerations, interpretability concerns, and real-time risk assessment using AI emphasize the importance of ensuring responsible, transparent, and clinically viable AI-driven predictions within healthcare systems.

This comprehensive review explores various dimensions of AI in cancer prediction, delving into intricacies, challenges, and transformative potential across different methodologies. By scrutinizing aspects such as comparative analyses, deep learning models, multi-omics integration, ethical considerations, real-time risk assessments, and longitudinal studies, the review aims to illuminate the dynamic landscape of AI-driven cancer prediction. The insights derived from this exploration not only pave the way for improved predictive models but also hold promise in significantly impacting early detection, precision medicine, and ultimately enhancing patient outcomes in the complex realm of oncology.

Ground-breaking in the field of oncology, deep learning models have emerged as powerful tools for the early detection of specific cancers, fundamentally reshaping the landscape. These models utilize intricate neural network architectures to analyse medical imaging data. Convolutional Neural Networks (CNNs), a prominent category within deep learning, have demonstrated remarkable effectiveness in identifying abnormalities indicative of various cancers within imaging scans like MRIs, CT scans, mammograms, and histopathological images. Their excellence lies in their ability to discern intricate patterns and features within these images, enabling the identification of subtle anomalies that might escape human perception. For instance, in breast cancer detection, CNNs can distinguish micro calcifications or architectural distortions signalling malignancy. Similarly, when diagnosing lung cancer through CT scans, these models can identify nodules or masses suggesting potential tumours.

Utilizing AI for Cancer Prediction through Multi-Omics Data Integration:

The integration of multi-omics data into AI-driven cancer prediction represents an innovative approach that is reshaping oncology research. Multi-omics data combines information from diverse biological sources, including genomics, transcriptomics, proteomics, metabolomics, and epigenetics. This holistic approach offers a profound molecular-level understanding of cancer mechanisms. AI algorithms, including machine learning and deep learning techniques, play a pivotal role in assimilating and analysing these intricate datasets. The objective is to uncover novel biomarkers, molecular signatures, and disease pathways, contributing to precise cancer prediction and prognosis. Genomic data provides insights into DNA variations linked to cancer susceptibility, while transcriptomic data helps identify dysregulated genes indicative of specific cancer types. Proteomic data sheds light on protein-level changes, offering information about cellular functions and signalling pathways in cancer. Integrating metabolomics data identifies metabolic signatures characteristic of different cancers, and epigenetic data elucidates regulatory mechanisms underlying cancer development. However, challenges such as data heterogeneity, dimensionality, and noise persist. AI techniques, including network-based analyses, feature selection, and integration frameworks, play a pivotal role in addressing these challenges, revealing meaningful patterns, reducing noise, and enhancing predictive accuracy. The synergy between AI-driven analyses and multi-omits data integration holds promise in advancing cancer risk assessment, early detection, treatment selection, and personalized medicine.

Ethical Considerations in AI-driven Cancer Prediction:

The ethical considerations surrounding the integration of AI in cancer prediction are multifaceted, encompassing pivotal aspects such as patient privacy, fairness, transparency, clinical decision-making, and patient autonomy.

Concerns about patient privacy and data security arise due to the reliance of AI algorithms on vast amounts of sensitive patient data. Achieving a balance between data access for research and predictive accuracy while upholding strict privacy standards remains a paramount challenge. Inherent biases in historical healthcare data may perpetuate in AI models, resulting in disparities in predictive accuracy across diverse demographics. Addressing algorithmic bias and ensuring fairness in predictions are crucial for equitable healthcare outcomes. The opacity of AI models presents another ethical challenge, as the lack of explain ability may hinder trust among clinicians and patients. Establishing transparent AI systems capable of elucidating predictions is pivotal for fostering confidence and comprehension in clinical settings. The symbiosis between AI-generated predictions and human expertise requires a delicate balance, ensuring that AI serves as a supportive tool augmenting rather than replacing healthcare professionals. The impact of AI predictions on patient autonomy raises concerns about informed decision-making, necessitating transparent communication about uncertainties and limitations of AI-generated insights. Addressing these ethical dimensions demands interdisciplinary collaboration, ongoing assessment, and a commitment to safeguarding patient rights, fairness, and trust in the evolving landscape of AI-driven cancer prediction within healthcare systems.

Real-time Cancer Risk Assessment Using AI:

Real-time Cancer Risk Assessment through AI represents a cutting-edge approach in oncology, revolutionizing how we predict, assess, and manage cancer risks dynamically. This paradigm utilizes AI to continuously analyse patient health data from various sources, enabling timely risk evaluations and personalized interventions. The process involves collecting real-time patient data from wearable devices, electronic health records (EHRs), and other monitoring systems. This amalgamated data, encompassing physiological metrics, lifestyle patterns, genetic markers, and environmental factors, provides a comprehensive and current patient profile. Efficient pre-processing, including data cleaning, normalization, and feature extraction, ensures accuracy and relevance for AI models. Advanced AI algorithms, such as machine learning and deep learning, analyse this dynamic patient data, continually learning and adapting to identify patterns or correlations indicating potential cancer risks or changes in a patient's health status. These models, trained on historical and real-time data, generate predictive risk scores or alerts, aiding healthcare professionals in early identification and proactive management of potential cancer risks. Interpretability remains crucial, and explaining the rationale behind risk assessments is vital for clinical acceptance and patient understanding.

Transfer Learning in Cancer Prediction:

Transfer learning, a prominent technique in AI, has gained attention in cancer prediction for its potential to enhance predictive model performance. This approach involves leveraging knowledge from one domain or dataset to improve learning and generalization on another related but different domain. In cancer prediction, transfer learning is particularly valuable when dealing with limited or heterogeneous data across cancer types. It allows knowledge transfer from well-established datasets or pre-trained models to aid in developing more accurate and efficient predictive models. Transfer learning addresses challenges related to data scarcity, especially for rare cancer types or datasets lacking sufficient samples for robust model training. By utilizing pre-trained models developed on larger, more diverse datasets, transfer learning enables the extraction and transfer of learned features, patterns, or representations to smaller or less abundant datasets. This enhances model performance by initializing or fine-tuning neural network architectures, such as convolutional neural networks (CNNs) or recurrent neural networks (RNNs), with transferred features. Transfer learning reduces computational costs and training time, as models initialized with pre-learned parameters require fewer iterations to converge. Despite its advantages, challenges exist, including domain differences between the source and target datasets, requiring careful adaptation or modification of transferred knowledge. Ethical considerations, including patient privacy, data sharing, and model transparency, remain essential when employing transfer learning techniques in cancer prediction, warranting close attention and regulatory adherence. Despite these challenges, the promising potential of transfer learning in enhancing the accuracy and efficiency of AI-based cancer prediction models highlights its significance in advancing cancer research and clinical practice.

Explainable AI in Cancer Prediction Models:

Explainable AI (XAI) is a critical aspect of cancer prediction models, ensuring transparency and trustworthiness in AI-driven decision-making within healthcare. XAI in cancer prediction models aims to elucidate the rationale behind predictions, making them interpretable and comprehensible to clinicians and patients. Model-agnostic methods, such as LIME (Local Interpretable Model-agnostic Explanations) or SHAP (Shapley Additive Explanations), are employed to generate explanations for specific predictions. These methods attribute predictions to features in the dataset, elucidating why a particular outcome was predicted. For instance, in cancer prediction based on medical imaging data, XAI methods can highlight regions within an image that influenced the prediction, aiding clinicians in understanding the model's decision-making process. Interpretable model architectures, such as decision trees or rule-based systems, are another aspect of XAI designed for transparent and understandable outputs. These models prioritize simplicity and transparency, ensuring clinicians can comprehend factors influencing predictions without requiring expertise in complex AI algorithms. AI in cancer prediction not only enhances model transparency but also fosters trust among healthcare professionals and patients. Understanding why a model makes specific predictions is crucial, especially in clinical settings where decisions impact patient care. Integrating XAI into cancer prediction models enhances their clinical utility, facilitating broader acceptance and adoption within the healthcare community. This ultimately contributes to more informed and collaborative decision-making processes in cancer diagnosis and treatment.

Challenges and Opportunities in Deploying AI for Cancer Prediction in Clinical Settings:

Implementing AI for cancer prediction within clinical settings presents challenges and opportunities. Complexities in data quality and integration, where disparate and heterogeneous clinical data hinder seamless aggregation and model training, pose a challenge. Regulatory compliance and ethical considerations surrounding patient privacy, consent, and model interpretability impact data access and trust in AI predictions among clinicians. Integrating AI into clinical workflows is challenging due to the black-box nature of some models, raising concerns about interpretability and acceptance among healthcare professionals. Transformative opportunities, however, include advancing diagnostics and personalized medicine, enabling early detection and tailored treatment plans based on individual patient profiles.

Methodology

Data Collection and Preparation: Aggregate diverse datasets, encompassing clinical records, imaging scans, genetic profiles, and pathology reports, from reputable healthcare institutions, research databases, and biobanks. Subsequently, cleanse the collected datasets by addressing missing values, correcting errors, normalizing numerical features, encoding categorical variables, managing class imbalance, and partitioning the data into training, validation, and test sets. Maintain consistency and fairness in pre-processing procedures across various algorithms.



Fig1: Methodology

Scoring categories of mitotic counts				
Field diameter (mm)	Area (mm^2)	Number of mitoses per 10 fields corresponding to:		
		Score 1	Score 2	Score 3
0.40	0.125	≤4	5 to 9	≥10
0.41	0.132	≤4	5 to 9	≥10
0.42	0.139	≤5	6 to 10	≥11
0.43	0.145	≤5	6 to 10	≥11
0.44	0.152	≤5	6 to 11	≥12
0.45	0.159	≤5	6 to 11	≥12
0.46	0.166	≤6	7 to 12	≥13
0.47	0.173	≤6	7 to 12	≥13
0.48	0.181	≤6	7 to 13	≥14

0.49	0.189	≤6	7 to 13	≥14
0.50	0.196	≤7	8 to 14	≥15
0.51	0.204	≤7	8 to 14	≥15
0.52	0.212	≤7	8 to 15	≥16
0.53	0.221	≤8	9 to 16	≥17
0.54	0.229	≤8	9 to 16	≥17
0.55	0.238	≤8	9 to 17	≥18
0.56	0.246	≤8	9 to 17	≥18
0.57	0.255	≤9	10 to 18	≥19
0.58	0.264	≤9	10 to 19	≥20
0.59	0.273	≤9	10 to 19	≥20
0.60	0.283	≤10	11 to 20	≥21
0.61	0.292	≤10	11 to 21	≥22
0.62	0.302	≤11	12 to 22	≥23
0.63	0.312	≤11	12 to 22	≥23
0.64	0.322	≤11	12 to 23	≥24
0.65	0.332	≤12	13 to 24	≥25
0.66	0.342	≤12	13 to 24	≥25
0.67	0.353	≤12	13 to 25	≥26
0.68	0.363	≤13	14 to 26	≥27
0.69	0.374	≤13	14 to 27	≥28

Table 1: Score categories according to field diameter, area and mitotic count.

Comparison of Machine Learning Algorithms: Algorithm Selection: Opt for machine learning algorithms such as CNN and RNN for evaluation. Conduct training and evaluation of each algorithm on pre-processed datasets using standardized procedures. Employ cross-validation techniques or holdout methods to assess the algorithms' performance metrics, including accuracy, sensitivity, specificity, and area under the curve (AUC). Statistical Analysis: Perform relevant statistical tests to compare algorithm performance and identify the most suitable algorithm(s) for cancer prediction based on various criteria.

Feature Selection and Model Development: Utilize AI techniques, incorporating machine learning and deep learning, to formulate personalized risk prediction models. Apply feature selection methods to pinpoint significant variables and train models on integrated datasets comprising genetic, lifestyle, and medical history data. Model Training and Validation: Train AI models using appropriate algorithms (e.g., neural networks, ensemble methods) on pre-processed datasets. Validate models using robust validation techniques, assessing accuracy, specificity, sensitivity, and other pertinent performance metrics. Ethical Considerations: Ensure compliance with ethical guidelines concerning patient data privacy, consent, and fairness in model development.

Interpretation and Reporting: Analysis of Feature Importance: Assess the significance of features influencing predictions in both the comparative analysis and personalized risk prediction models. Present results comprehensively, elaborating on the performance comparison among algorithms and the effectiveness of personalized risk prediction models. Utilize visualizations, tables, and statistical summaries to enhance clarity.

Limitations and Future Directions: Address encountered limitations, including data constraints, biases, or algorithmic challenges during the study. Propose potential avenues for future research, focusing on improvements in data collection, algorithm development, and ethical considerations in AI-driven cancer prediction.



Fig2: Cancer diagnosis report using 3929 images

The convergence of cyber security and cancer prediction data involves ensuring the security and privacy of sensitive healthcare information, as well as safeguarding the integrity of data used in cancer **prediction models.**

Conclusion

In the sphere of cancer prediction, the integration of Artificial Intelligence (AI) stands as a pioneering solution across various fields. Comparative analysis of machine learning algorithms offers valuable insights into diverse methodologies, aiding in the selection of optimal models. Deep learning models, particularly Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs), exhibit efficacy in early cancer detection. The integration of multi-omics data with AI unveils molecular intricacies, enabling precise predictions and personalized medicine. Ethical considerations underscore the importance of transparency, fairness, and patient autonomy. Real-time risk assessment and longitudinal studies, facilitated by AI, promise dynamic insights into cancer progression. Transfer learning addresses data gaps, while Explainable AI enhances trust in clinical settings. Challenges in deployment coexist with opportunities to revolutionize diagnostics and patient care in oncology. Ultimately, AI's role in personalized cancer risk prediction empowers proactive healthcare strategies, facilitating earlier detection and improved outcomes. The incorporation of cybersecurity measures ensures the security and privacy of cancer prediction data, fostering trust among stakeholders while safeguarding sensitive information.

References

[1] Royal College of Pathologists and National Coordinating Committee for Breast Pathology (2016). Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for

histological reporting of breast cancer. Available from: https://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html (Accessed 26th March 2020).

[2] Harvey JM, Clark GM, Osborne CK and Allred DC (1999). Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J Clin Oncol* 17(5):1474-1481.

[3] College of American Pathologists (2020). *Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast*. Available from: https://documents.cap.org/protocols/cp-breast-biomarker-20-1400.pdf (Accessed 22nd September 2020).

[4] Harbeck N, Gnant M. Breast cancer. *Lancet*. 2017;**389**(10074):1134–1150. doi: 10.1016/S0140-6736(16)31891-8

[5] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;**71**(3):209–249. doi: 10.3322/caac.21660

[6] Afolabi LO, Afolabi MO, Sani MM, et al. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy. *Clinical Translat Immunol*. 2021;**10**(6):e1286. doi: 10.1002/cti2.1286

[7] World Health Organization. © International Agency for Research on Cancer, 2020. Cancer Today. Available from:https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0. Accessed June 20, 2023.

[8] Ahmad M, Khan Z, Rahman ZU, Khattak SI, Khan ZU. Can innovation shocks determine CO2 emissions (CO2e) in the OECD economies? A new perspective. *Econ Innov New Technol*. 2021;**30**(1):89–109. doi: 10.1080/10438599.2019.1684643

[9] Gaur K, Jagtap MM. Role of artificial intelligence and machine learning in prediction, diagnosis, and prognosis of cancer. *Cureus*. 2022;**14**(11). doi: 10.7759/cureus.31008

[10] Dananjayan S, Raj GM. Artificial Intelligence during a pandemic: the COVID −19 example. *Int J Health Plann Manage*. 2020;**35**:1260–1262. doi: 10.1002/hpm.2987

[11] Iqbal MJ, Javed Z, Sadia H, et al. Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future. *Cancer Cell Int*. 2021;**21**(1):1–11. doi: 10.1186/s12935-021-01981-1

[12] Huang S, Yang J, Fong S, Zhao Q. Artificial intelligence in cancer diagnosis and prognosis: opportunities and challenges. *Cancer Lett*. 2020;**471**:61–71. doi: 10.1016/j.canlet.2019.12.007

[13] Hollon TC, Pandian B, Adapa AR, et al. Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks. *Nat Med*. 2020;**26**(1):52–58. doi: 10.1038/s41591-019-0715-9